跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
謝 政毅
主治醫師
,
臺北醫學大學附設醫院
https://orcid.org/0000-0001-8408-7948
電子郵件
951007
tmuh.org
tw
h-index
103
引文
5
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2010
2019
每年研究成果
概覽
指紋
網路
研究成果
(8)
類似的個人檔案
(6)
指紋
查看啟用 Cheng-I Hsieh 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Pancreas Carcinoma
66%
Breast Cancer
66%
Adjuvant Chemotherapy
66%
Colon Cancer
66%
Life Sustaining Treatment
66%
Terminal Illness
66%
Patient Care
66%
Treatment Response
66%
Drug Therapy
66%
Cetuximab
66%
Bevacizumab
66%
Oncologist
62%
Pancreas Cancer
50%
Nausea and Vomiting
50%
Group Therapy
50%
Disease
40%
Nutritional Support
37%
Fluorouracil
33%
Overall Survival
33%
Gemcitabine
33%
Cisplatin
33%
Oncology
28%
Primary Health Care
19%
Emergency Department
19%
Adverse Event
16%
Progression Free Survival
16%
Combined Therapy
16%
Cytostatic Agent
16%
Intubation
14%
Artificial Respiration
14%
Proteus Syndrome
13%
Cancer Registry
13%
Surgeon
13%
Chemotherapy Regimens
13%
Proportional Hazards Model
13%
Primary Tumor
13%
Surgical Margin
13%
Recurrent Disease
13%
Kaplan Meier Method
13%
Colectomy
13%
Recurrence Risk
13%
Disease Free Survival
13%
Health Outcomes
9%
Mammography
9%
Propensity Score Matching
9%
Ambulatory Care
9%
Breast Ultrasound
9%
Retrospective Cohort Study
9%
End of Life Care
7%
Intensive Care Unit
7%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Prevalence
66%
Vinorelbine
66%
Pancreas Carcinoma
66%
Docetaxel
66%
Bevacizumab
66%
Lung Cancer
66%
Clinical Trial
66%
Malignant Neoplasm
66%
Cetuximab
66%
Cancer Staging
66%
Lower Urinary Tract Symptom
66%
Sunitinib
66%
Nausea and Vomiting
50%
Pancreas Cancer
50%
Overall Survival
46%
Fluorouracil
33%
Gemcitabine
33%
Chemotherapy
26%
Protein Tyrosine Kinase Inhibitor
26%
Cytostatic Agent
16%
Adverse Event
16%
Progression Free Survival
16%
Disease Exacerbation
13%
Vasculotropin
13%
9 [(4 Acetyl 3 Hydroxy 2 Propylphenoxy)methyl] 3 (1h Tetrazol 5 Yl) 4h pyrido[1,2 A]pyrimidin 4 One
13%
Protein Tyrosine Kinase
13%
Epidermal Growth Factor Receptor
13%
Combination Therapy
13%
Nursing and Health Professions
Lower Urinary Tract Symptom
66%
Life Sustaining Treatment
66%
Prevalence
66%
Quality of Life
66%
Malignant Neoplasm
66%
Nutritional Support
37%
Intubation
14%
Artificial Respiration
14%
Nose Feeding
7%
End of Life Care
7%
Intensive Care Unit
7%
Resuscitation
7%
Latent Class Analysis
7%
Heart Massage
7%
